Literature DB >> 35324269

Understanding T cell responses to COVID-19 is essential for informing public health strategies.

Santosha Vardhana1,2,3, Lance Baldo4, William G Morice5, E John Wherry6,7,8.   

Abstract

Durable T cell responses to SARS-CoV-2 antigens after infection or vaccination improve immune-mediated viral clearance. To date, population-based surveys of COVID-19 adaptive immunity have focused on testing for IgG antibodies that bind spike protein and/or neutralize the virus. Deployment of existing methods for measuring T cell immunity could provide a more complete profile of immune status, informing public health policies and interventions.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35324269     DOI： 10.1126/sciimmunol.abo1303

Source DB:  PubMed          Journal:  Sci Immunol        ISSN： 2470-9468


  11 in total

1.  SARS CoV-2 (Delta Variant) Infection Kinetics and Immunopathogenesis in Domestic Cats.

Authors:  Miruthula Tamil Selvan; Sachithra Gunasekara; Ping Xiao; Kristen Griffin; Shannon R Cowan; Sai Narayanan; Akhilesh Ramachandran; Darren E Hagen; Jerry W Ritchey; Jennifer M Rudd; Craig A Miller
Journal:  Viruses       Date:  2022-06-01       Impact factor: 5.818

2.  Measuring SARS-CoV-2 T cell immunity with a scalable qPCR-based assay.

Authors: 
Journal:  Nat Biotechnol       Date:  2022-06-17       Impact factor: 68.164

3.  T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.

Authors:  Yongzheng Li; Xiuwen Wang; Junyan Jin; Zhenglai Ma; Yan Liu; Xin Zhang; Bin Su
Journal:  J Med Virol       Date:  2022-05-06       Impact factor: 20.693

Review 4.  Understanding COVID-19 Vaccines Today: Are T-cells Key Players?

Authors:  Areez Shafqat; Tarek Z Arabi; Belal N Sabbah; Humzah S Abdulkader; Shameel Shafqat; Adhil Razak; Junaid Kashir; Khaled Alkattan; Ahmed Yaqinuddin
Journal:  Vaccines (Basel)       Date:  2022-06-06

5.  High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients.

Authors:  Hendrik Karsten; Leon Cords; Tim Westphal; Maximilian Knapp; Thomas Theo Brehm; Lennart Hermanussen; Till Frederik Omansen; Stefan Schmiedel; Robin Woost; Vanessa Ditt; Sven Peine; Marc Lütgehetmann; Samuel Huber; Christin Ackermann; Melanie Wittner; Marylyn Martina Addo; Alessandro Sette; John Sidney; Julian Schulze Zur Wiesch
Journal:  Clin Transl Immunology       Date:  2022-08-09

Review 6.  Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines.

Authors:  Alessandro Sette; Shane Crotty
Journal:  Immunol Rev       Date:  2022-06-22       Impact factor: 10.983

7.  Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies.

Authors:  Roberto Alfonso-Dunn; Jerry Lin; Vanessa Kirschner; Joyce Lei; Grant Feuer; Michaela Malin; Jiayuan Liu; Morgan Roche; Saud A Sadiq
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

8.  Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity.

Authors:  Daniel Leung; Xiaofeng Mu; Jaime S Rosa Duque; Samuel M S Cheng; Manni Wang; Wenyue Zhang; Yanmei Zhang; Issan Y S Tam; Toby S S Lee; Jennifer H Y Lam; Sau Man Chan; Cheuk Hei Cheang; Yuet Chung; Howard H W Wong; Amos M T Lee; Wing Yan Li; Sara Chaothai; Leo C H Tsang; Gilbert T Chua; Kai-Ning Cheong; Elaine Y L Au; Janette S Y Kwok; Koon Wing Chan; Patrick C Y Chong; Pamela P W Lee; Marco H K Ho; Tsz Leung Lee; Wenwei Tu; Malik Peiris; Yu Lung Lau
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

9.  A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines.

Authors:  Joey Ming Er Lim; Shou Kit Hang; Smrithi Hariharaputran; Adeline Chia; Nicole Tan; Eng Sing Lee; Edwin Chng; Poh Lian Lim; Barnaby E Young; David Chien Lye; Nina Le Bert; Antonio Bertoletti; Anthony T Tan
Journal:  Cell Rep Med       Date:  2022-10-06

10.  COVID-19 infection in primary central nervous system lymphoma treatment: Who is most at risk?

Authors:  Sean H Lim
Journal:  Br J Haematol       Date:  2022-08-26       Impact factor: 8.615
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.